Genta Incorporated (PINK: GNTA), a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer, is seeing a sharp rise in its shares in trading today.
GNTA shares are currently trading 30% higher at $0.0013 on above average volume of 263.58 million.
Genta Incorporated shares are surging after the company announced results from its Phase 2 clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer.
Dr. Loretta M. Itri, President of Pharmaceutical Development and Chief Medical Officer, at Genta, said that the data confirms results from GNTA’s prior study, both of which show significant activity for tesetaxel in patients with advanced HER2-negative breast cancer. Dr. Itri noted that GNTA is also exploring an alternate dosing schedule in this population using weekly treatment.
Recent Comments